Semaglutide Health Outcomes and Patient Adherence in Australia

Study acronym: SHAPED-AU
StatusNot Yet Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Novo Nordisk
269 trials monitored
See 14 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
This observational study aims to generate real-world evidence on the use of semaglutide in adults with overweight or obesity receiving care through a digital weight loss service (DWLS) programme in Australia. The study will evaluate treatment patterns, adherence, quality of life, safety, and other health outcomes associated with semaglutide use in routine clinical practice. Information will be collected from data generated during standard clinical care, and no study-specific treatment or procedures will be required.
Trial Details
NCT Number NCT07881770
Lead Sponsor Novo Nordisk A/S
Collaborators: Eucalyptus Services Pty Ltd
Conditions
(from sponsor)		 Overweight, Obesity
Related terms Obesity, Overweight
Enrollment 10,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov